Aclaris Therapeutics Inc. (ACRS) Fundamentals

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
SHARE INFORMATION
Market Cap$ 920,827,718
Shares Outstanding66,581,903
Float64,174,217
Percent Float96.38%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 6,761,000
Latest Fiscal EPS$ -1.63
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions313
Institutional Holdings Date2022-06-30
Institutional Bought Previous 3 Months7,950,390
Institutional Holdings Percent123.3%
Institutional Sold Previous 3 Months7,572,752
Insider Holdings Date2022-05-31
Insider Bought Previous 3 Months1,079,676
Insider Holdings Percent4.2
Insider Sold Previous 3 Months347,567
Insider Shares Owned2,578,076
TRADING INFO
52 Week High$ 19.97
52 Week Low$ 9.26
52 Week High Change$ -19.64
21 Day Moving Average$ 14.7405
21 Day Extended Moving Average$ 14.3609
50 Day Moving Average$ 13.4226
50 Day Extended Moving Average$ 14.1177
200 Day Moving Average$ 14.4693
200 Day Extended Moving Average$ 14.4468
10 Day Average Volume582,905
20 Day Average Volume458,895
30 Day Average Volume437,683
50 Day Average Volume428,191
Alpha0.026571
Beta0.6080
Standard Deviation0.369437
R20.006472
7 Day Price Change$ -0.59
7 Day Percent Change-4.09%
21 Day Price Change$ -0.61
21 Day Percent Change-4.22%
30 Day Price Change$ 0.45
30 Day Percent Change3.36%
Month to Date Price Change$ -0.13
Month to Date Percent Change-0.93%
Quarter to Date Price Change$ -0.13
Quarter to Date Percent Change-0.93%
180 Day Price Change$ -0.71
180 Day Percent Change-4.88%
200 Day Price Change$ -0.20
200 Day Percent Change-1.43%
Year to Date Price Change$ -0.71
Year to Date Percent Change-4.88%

Aclaris Therapeutics Inc. (ACRS) Key Ratios

PROFITABILITY
EBIT Margin-1,140.3%
EBITDA Margin-1,127.2%
Pre-Tax Profit Margin-2,098.6%
Profit Margin Count0.0%
Gross Margin15.4%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 4,613,000
Revenue Per Share$ 0.0693
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book5.30
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio11.40
Leverage Ratio1.30
Quick Ratio10.80
Long Term Debt To Capital0.04
VALUATION MEASURES
PE Ratio-10.10
Enterprise Value$ 741,921,718
Price to Sales199.6158
Price to Free Cash-18.80
PE High Last 5 Years-2.00
Price To Book5.10
Price To Cash Flow0.00
PE Low Last 5 Years-9.40
Price to Tangible Book5.30
MANAGEMENT EFFECTIVENESS
Receivables Turnover7.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-42.70
Return on Equity-56.53
Return on Capital-55.07

Aclaris Therapeutics Inc. (ACRS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorPricewaterhouseCoopers LLP
CEONeal Walker
Emplyoees77
Last AuditUQ
CIK0001557746
IndustryMedical Diagnostics & Research
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address640 Lee Road
Suite 200
Wayne, PA 19087
Websitehttps://www.aclaristx.com
Facsimile+1 484 320-2344
Telephone+1 484 324-7933
Emailmtung@aclaristx.com


Your Recent History
NASDAQ
ACRS
Aclaris Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.